LETTERS TO THE EDITOR

Antibiotic treatment of suspected neonatal meningitis

Sir,—The annotation on antibiotic treatment of suspected neonatal meningitis suggests that optimal treatment of this thankfully rare disorder is still not clear. The suggested array of antibiotic treatment and combined routes of administration may provide cover against a wide range of organisms, but is such treatment in the best interests of every patient? In a sick hypotensive infant who may already have compromised renal function the combination of aminoglycoside and cephalosporin may exacerbate the problem. To state that 'Gentamicin should be used primarily to treat the associated septicaemia' is misleading if the implication is that cephalosporins are incapable of doing this. Is there any evidence to suggest that cefotaxime is ineffective in the treatment of bacteremia in neonates? I am concerned by the conviction of the authors in their management proposals. To begin a paragraph stating 'there is no doubt in our minds that intraventricular treatment should be used' and end it with 'there has been no study of intraventricular treatment... and little information on the ventricular drug concentration achieved after systemic treatment alone in dilated ventricles' is perhaps a little rash in view of the finding of a markedly increased mortality after intraventricular treatment in the American study. The conclusion of McCracken and colleagues was that 'intraventricular therapy cannot be recommended for the routine management of neonatal meningitis caused by Gram negative enteric bacilli'. In the absence of a further randomised multicentre trial it is surely ill advised to recommend the adoption of this invasive and potentially dangerous mode of treatment as the standard treatment in neonatal Gram negative meningitis with ventricular dilatation.  

A SHORT INSTITUTE OF CHILD HEALTH, EQUAL LIVERPOOL CHILDBIRTHS HOSPITAL AIDER HEY, Evesham Road, Liverpool L12 2AP


Sir,—The main thrust of the annotation on treatment of neonatal meningitis is the recommendation that antibiotics should be used intraventricularly as well as intravene-

ously, particularly in the babies infected with Gram negative enteric organisms. The authors mention the only significant study in the field, that of McCracken et al (1980),2 only to dismiss its findings (there was a higher mortality in the group treated with intraven-

tricular therapy) on the grounds that many of

the infants had salmonella infection and were treated relatively late. This interpretation does not take into account the advances in our understanding of the pathophysiology of meningitis, and is likely to lead to a simplistic approach to clinical management. It is now known that the inflammatory response in meningitis (and in many other infective conditions) is mediated through the release of cyto-

kines, particularly tumour necrosis factor and interleukin-1, from cells after their exposure to bacterial endotoxin and other cell wall material. Interleukin-1 concentrations in the cerebrospinal fluid correlate well with the degree of meningeal inflammation and with the outcome. Ventricular cerebrospinal fluid samples from the 1970s study performed by McCracken and his colleagues were stored in the deep freeze at the time, and their endotoxin and cytokine concentrations have recently been examined by Mustafa et al (1989). They found increased endotoxin and very much higher interleukin-1 concentrations in the cerebrospinal fluid of the group treated with intraventricular antibiotics than in those only treated intravenously. Endotoxin concentrations of 78 ng/ml in the intraventricular group compared with 22 ng/ml in those given intravenous treatment alone. Similarly, mean interleukin-1 concentrations as high as 5024 pg/ml in the patients given intravenous gentamicin contrasted with mean concentra-

tions of 87 pg/ml in patients treated with intra-
venous antibiotics alone. This effect is likely to be due to bacterial hyperendotoxemia and other bacterial cell wall products with very high local concentrations of intraventricular gentamicin. The resulting cytokine production would appreciably exacerbate the inflam-

matory response of the brain. The advice that although intraventricular antibiotics may be appropriate treatment in neonatal meningitis (although there is little firm evidence either way), it is important to modulate the resultant inflammatory response as well as to kill the bacteria. Considerable recent work, particu-

larly from McCracken's group, has shown that dexamethasone can do this both in the exper-

imental animal model and children with meningitis. Until we recognise that the treat-

ment of meningitis should include the suppression of excessive inflammation as well as the destruction of the pathogen we are unlikely to improve the prognosis in this serious and distressing disease.

M J TARLOW

Department of Paediatrics, East Birmingham Hospital, Bordesley Green East, Birmingham B9 5ST


Dr Rennie and Gandy comment: Thank you for giving us the opportunity to reply to the comments regarding our editorial. Opinions regarding the benefits of intraventricular treatment in neonatal Gram negative meningitis are likely to continue to differ for some time: our recommendations constitute what we consider to be minimal guidelines for the management of this serious and rare disease. We remain of the opinion, shared with Pearse and Robertson, that a ventri-

cular tap should be performed if the ventricles are large or the infant is failing to respond to treatment after 24 hours. Intraventricular treatment should be given via a Rickham reservoir to babies with ventriculitis. We do not avoid this treatment because of the conclu-

sions of the Neonatal Meningitis Cooperative Study Group because patients were enrolled in this study more than 10 years ago, before the widespread availability of cranial ultrasound or the third generation cephalosporins. Much of the discussion pertaining to this work has been well rehearsed before, including the fact that only 20 cases were actually neonates suffering from Salmonella meningitis. The combination of cefotaxime with another drug such as gentamicin was suggested because of the evidence in favour of synergism, the improved outlook in granulo-

matous meningitis cases and the demonstration of rapid bacterial killing. We use a single agent when the baby is improving and sensitivity results are available. Ceftriaxone monotherapy seems promising in adults and may prove useful in the newborn. This statement is purposely vague yet precisely the type of complication that led us to suggest transfer of such cases to centres with intensive care facilities. 

Dr Tarlow's suggestion that neonatologists should consider high dose dexamethasone is an interesting one and we are aware of the evidence suggesting a reduction in neurological sequelae in older children, most of whom were suffering from haemophilus infection 2. A trial of dexamethasone treatment in neonatal meningitis is planned. 3 The dose suggested is large and high dose steroid treatment has proved detrimental in shock. This may be more of a problem for the neonate with Gram negative meningitis than it has been in the general paediatric population.

1 Pearse R, Robertson NRC. Infection in the new-

3 Allen JD, Meelerling RC. Management of infec-

When should the coeliac patient have an intestinal biopsy?

Sir,—Gluten challenges and intestinal biopsies are stressful procedures both for coeliac patients and for the doctors dealing with them. While we recognise that the time has
come to reconsider the 1970 European Society of Paediatric Gastroenterology and Nutrition (ESPGAN) diagnostic criteria for gluten sensitive enteropathy.1 We do not entirely agree with the timing of the diagnostic intestinal biopsy proposed by our Italian Group of Paediatric Gastroenterology at the meeting in Trieste, May 1987, and recently published.2 A multicentre study indicates that at least in Italy the vast majority of diagnoses of gluten sensitive enteropathy (more than 90%) are made in young children who are referred with signs of malabsorption or who are then found positive for the antigliadin antibody test. At the Trieste conference it was stated that these so called typical cases do not need a gluten challenge and can be readily and definitely diagnosed by a single biopsy specimen showing a flat mucosa at the first work up.

Looking back on our hundreds of biopsies we have noticed that whenever the clinical and laboratory data strongly suggested gluten sensitive enteropathy, we nearly always found a flat mucosa at the first intestinal biopsy. It appears then that the initial biopsy recommended by ESPGAN and retained by the Trieste recommendations is seldom informative as its result is highly predictable in typical patients. In these cases (supported by a positive antigliadin antibody test and abnormal intestinal permeability test) we suggest that the initial biopsy is avoided and a six to 12 month period of gluten free diet is commenced (figure).

As the first years of a gluten free diet seem to have an imprinting effect on the long term compliance, we believe that the gluten challenge is, at present, unavoidable in the youngest patients because it demonstrates the persistence of the disease to the patients’ family. At the end of a three to six month period of gluten challenge (or less if symptoms develop) a biopsy is highly recommended as the relapse is sometimes evident only at the histological level. This single biopsy specimen will confirm the diagnosis of gluten sensitive enteropathy in most cases. If the mucosa looks normal the patient can be left on a free diet and periodically checked to exclude the possibility of a late response to gluten. In our opinion a short period of gluten ingestion, as we propose, should not expose the patient to significant risks.

The above approach is less invasive than the ESPGAN scheme and fully exploits the diagnostic role of the antigliadin antibody test at the first assessment of the patient. We also suggest adding the sugar intestinal permeability test, which has proved to be a reliable screening procedure for gluten sensitive enteropathy.3 For atypical or late onset cases we agree that an intestinal biopsy is always mandatory during the first diagnostic phase. A conclusive note of caution is added. It is well known that long term treatment of gluten sensitive enteropathy is often unsatisfactory.4 This is especially true for patients who have found ‘sensitive’ doctors who are overzealous in their wish to avoid unpleasant biopsies. So far we have followed the ESPGAN diagnostic criteria for coeliac disease with satisfactory results both for patients and for us. Nevertheless, in the light of the new, non-invasive diagnostic tools, we also agree on the need of revising the ESPGAN recommendations. This attempt should be made with the contribution of experts from several European centres.

Dr Walker comments:

The value of a non-invasive test of growth hormone secretion in children would be immense. Although of considerable promise, the study of Walker and colleagues does not yet justify the general introduction of urinary growth hormone estimations and more validation is necessary to establish the full characteristics of this potentially valuable addition to our range of investigations.


Urinary growth hormone excretion

Sir,—The paper by Walker and colleagues on the use of urinary growth hormone excretion as a screening test for growth hormone deficiency is of great interest.1 Words of caution are needed, however, before universal adoption of this test by paediatricians and general practitioners as already proposed.2

Of the two clinical groups studied, one (group 2) consisted of patients with previously diagnosed growth hormone deficiency who had been treated for variable periods with growth hormone. It is therefore highly probable, though not stated in the paper, that the timing of the urinary and serum investigations in this group for growth hormone deficiency is still under study for a considerable period, with the serum investigations at the time of diagnosis preceding the urinary one by months or years. In effect the urinary growth hormone estimation has been estimated retrospectively, which makes it difficult to evaluate its usefulness as a prospective test. Little if anything is known about deterioration of growth hormone secretion with time in patients with growth hormone deficiency, especially if they are on replacement treatment. Such data should not be used in the evaluation of the prospective role of urinary growth hormone excretion as a screening test for growth hormone deficiency.

The two different methods of deriving comparisons between overnight urinary growth hormone excretion and peak serum growth hormone concentration after stimulation makes the value of combining the data to conclude the paper coefficient suspect. In addition, as the authors themselves state, urinary growth hormone excretion is log distributed which invalidates regression analysis. Examination of the figure would suggest that at least for the subjects who were growth hormone deficient, if any correlation exists at all it could possibly be negative. There are clearly several factors that may influence urinary growth hormone excretion, and more detailed statistical analysis of the separate groups might have been more informative. The correlation coefficients would of course have been less impressive.

The value of a non-invasive test of growth hormone secretion in children would be immense. Although of considerable promise, the study of Walker and colleagues does not yet justify the general introduction of urinary growth hormone estimations and more validation is necessary to establish the full characteristics of this potentially valuable addition to our range of investigations.
When should the celiac patient have an intestinal biopsy.

C Catassi, G Natalini, M Rossini, I M Ratsch, G V Coppa and P L Giorgi

Arch Dis Child 1990 65: 810-811
doi: 10.1136/adc.65.7.810-c

Updated information and services can be found at:
http://adc.bmj.com/content/65/7/810.2.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/